• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Trump outlines new plan to lower Medicare drug prices, end ‘rigged’ system

Share:

November 5, 2018

Highlights on this story:
  • President Donald Trump outlined a plan Thursday that would allow Medicare to start negotiating drug prices to bring costs in line for its Part B coverage with what other nations pay for the same drugs.
  • HHS Secretary Alex Azar released a report earlier Thursday that said the U.S. pays 1.8 times more for the exact same drugs as other nations.

President Donald Trump outlined a plan Thursday he said would allow Medicare to lower drug prices for its Part B coverage and end this “rigged system” that allows other countries to pay less than the U.S. for the same drugs.

Under the administration’s proposal, the Department of Health and Human Services would permit Medicare to create a new payment model that would bring drug prices in line with what other nations pay.

HHS estimates $17 billion in program savings over five years, it said in a press release. The agency is trying to issue a formal rule early next year with the new payment model taking effect in 2020, HHS said.

“For decades, other countries have rigged the system so that American patients are charged much more … for the exact same drug,” Trump said in his speech at HHS headquarters in Washington.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Americans pay more so that other countries can pay less,” Trump said. “The government pays whatever price the drug companies ask … not any more.”

The SPDR S&P Pharmaceuticals index, which tracks drug stocks, was more than 2 percent higher early afternoon Thursday.

In May, Trump said it was time to end the “global freeloading once and for all,” referring to how some countries set price controls and therefore pay less for drugs than Americans, while U.S. companies invest in research and drug development.

Health and Human Services Secretary Alex Azar released a report earlier in the day that said the U.S. pays 1.8 times more, and sometimes four times as much, for prescriptions covered by Medicare Part B than other nations.

“The United States will finally be able to confront one of the most unfair practices … that drives up the cost of medicine,” Trump said. “For decades other countries have rigged the system so that American patients are charged much more, and in some cases much, much more for the exact same drug,” he said.

Medicare reimburses the list price of the drug plus 6 percent, so capping price increases could help lower the program’s costs. Total Medicare drug spending reached $162 billion in 2015, according to data from the Centers for Medicare and Medicaid Services.

“Because @POTUS wants to end global freeloading, we compared prices for the most costly physician-administered drugs that are covered and paid for by Medicare Part B,” Azar tweeted. The “prices for Part B drugs in America exceed the prices paid in countries with similar economic conditions.”

Date: November 5, 2018

Source: CNBC

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Pfizer’s DMD gene therapy safety data hand advantage to SareptaPfizer’s DMD gene therapy safety data hand advantage to Sarepta
  • Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care PartnershipHistogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
  • BiomX Acquires APT | Advancing Phage Therapy InnovationsBiomX Acquires APT | Advancing Phage Therapy Innovations
  • Stasis Labs Launches App-Connected Remote Patient Monitoring Platform in UsStasis Labs Launches App-Connected Remote Patient Monitoring Platform in Us
  • Itamar Medical Acquires Technology and Assets of Spry HealthItamar Medical Acquires Technology and Assets of Spry Health
  • Devoted Health Secures $175M to Expand Medicare Advantage Plans for SeniorsDevoted Health Secures $175M to Expand Medicare Advantage Plans for Seniors
  • Securing, controlling and monetising genomic data with blockchain technologySecuring, controlling and monetising genomic data with blockchain technology
  • Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic TherapeuticsCybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications